Ezetimibe

證據等級: L5

預測適應症: 10 個

Ezetimibe: From Hypercholesterolemia to Hyperlipoproteinemia

One-Sentence Summary

Ezetimibe is a selective cholesterol absorption inhibitor globally established for reducing elevated LDL-cholesterol in hypercholesterolemia, though it is not currently registered in Singapore. The TxGNN model predicts it may be effective for Hyperlipoproteinemia — a prediction tightly aligned with its known mechanism of action — with multiple completed Phase 3 trials and 19 publications supporting this direction. This case represents a high-confidence, mechanistically validated prediction, where the primary action required is Singapore regulatory registration rather than exploratory clinical development.

Quick Overview

Item	Content
Original Indication	Hypercholesterolemia (globally approved; not registered in Singapore)
Predicted New Indication	Hyperlipoproteinemia
TxGNN Prediction Score	99.63%
Evidence Level	L1
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence package. Based on established pharmacological knowledge, Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter located in the intestinal brush-border membrane. This blocks absorption of both dietary and biliary cholesterol, reducing delivery of cholesterol to the liver. As a compensatory response, hepatic LDL receptors are upregulated, leading to increased clearance of LDL particles from the bloodstream and a net reduction in plasma LDL-C of approximately 15–25% as monotherapy — and greater reductions when combined with a statin.

Hyperlipoproteinemia encompasses a spectrum of disorders defined by elevated plasma lipoprotein concentrations (LDL, VLDL, IDL, and remnant particles), all directly targeted by Ezetimibe's mechanism. Unlike statins, which suppress cholesterol synthesis via HMG-CoA reductase inhibition, Ezetimibe blocks the absorption pathway — a complementary approach targeting a different node in the lipoprotein metabolic network. This dual-pathway rationale has been validated clinically: the landmark IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin reduced major cardiovascular events beyond what statin therapy alone could achieve. The mechanistic link to hyperlipoproteinemia pathophysiology is therefore both direct and well-established.

The TxGNN model's 99.63% confidence score reflects the tight alignment between Ezetimibe and hyperlipoproteinemia. Multiple major regulatory agencies — including the FDA (Zetia®, Vytorin®), EMA (Ezetrol®, Inegy®), and Japan's PMDA (Zetia®) — have approved Ezetimibe for hypercholesterolemia, and international guidelines (EAS 2013, ACC/AHA) recommend it as first-line adjunct therapy. The fact that Ezetimibe is not yet registered in Singapore despite this robust global evidence base makes this an actionable regulatory filing opportunity rather than a traditional exploratory repurposing case.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00271817	Phase 3	Completed	1,220	Ezetimibe/Simvastatin co-administered with Niacin in Type IIa or IIb hyperlipidemia — core efficacy and safety evidence for the ezetimibe-based combination approach
NCT02451098	Phase 3	Completed	385	Atorvastatin+Ezetimibe combination vs. atorvastatin monotherapy in primary hypercholesterolemia — multicenter, randomized, double-blind factorial design
NCT00651560	Phase 3	Completed	167	Vytorin (ezetimibe+simvastatin) vs. atorvastatin in dyslipidemia — assessed ATP-III lipid goal achievement and cardiovascular risk reduction
NCT03884452	Phase 3	Completed	50	Ezetimibe 10 mg added to atorvastatin or simvastatin in homozygous familial hypercholesterolemia — Phase 3 efficacy and safety evaluation
NCT02748057	Phase 3	Completed	135	52-week safety and tolerability of ezetimibe+rosuvastatin (MK-0653H) in Japanese patients with inadequate LDL-C control on monotherapy
NCT01043380	Phase 4	Completed	245	PRECISE-IVUS: Compared cholesterol absorption inhibitor (ezetimibe arm) vs. synthesis inhibitor on coronary plaque regression measured by intravascular ultrasound
NCT05661552	Phase 4	Completed	108	Early initiation of evolocumab combined with statin+ezetimibe in ACS patients undergoing PCI — evaluated lipid profile changes
NCT02942602	NA	Completed	58	Ezetimibe's effect on HDL function and composition in hyperlipidemia — mechanistic evidence for benefits beyond LDL reduction
NCT00704535	N/A	Completed	4,105	Post-marketing surveillance of ezetimibe safety, tolerability, and efficacy in Filipino patients with hypercholesterolemia — large real-world dataset
NCT04895098	N/A	Completed	1,000	Retrospective observational study comparing statin monotherapy vs. statin+ezetimibe in both primary and secondary CVD prevention

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40347969	2025	Phase 3 RCT (TANDEM)	The Lancet	Fixed-dose obicetrapib+ezetimibe combination significantly reduced LDL-C vs. placebo — confirms ezetimibe's ongoing role as a cornerstone partner in novel combination therapies
41206969	2026	Phase 3 RCT	JAMA	Oral PCSK9 inhibitor enlicitide in HeFH patients on background statin+ezetimibe — validates ezetimibe as the established standard-of-care foundation
23956253	2013	Guideline/Consensus	European Heart Journal	EAS consensus: ezetimibe recommended alongside statins for LDL-C reduction and coronary heart disease prevention in familial hypercholesterolemia
25939291	2015	Review	Cardiology Clinics	FH management overview: ezetimibe identified as key second-line agent for LDL-C reduction and cardiovascular event prevention alongside statins and LDL apheresis
34480646	2021	Review	Current Cardiology Reports	FH global burden and management: ezetimibe highlighted as essential guideline-recommended component of lipid-lowering regimens for high-risk patients
29219151	2017	Review	Nature Reviews Disease Primers	Comprehensive FH disease primer: ezetimibe's mechanism of intestinal cholesterol absorption inhibition and its clinical role in LDL-C management reviewed in detail
33766264	2021	Review	Journal of the American College of Cardiology	Emerging LDL-C lowering therapies (JACC Focus Seminar): ezetimibe positioned as the established second-tier foundation upon which newer agents (inclisiran, bempedoic acid) are added
35593194	2022	Review	Journal of Cardiovascular Pharmacology and Therapeutics	Comprehensive PCSK9 inhibitor landscape review: ezetimibe cited as standard alternative lipid-lowering therapy for statin-intolerant patients
38599725	2024	Review	Indian Heart Journal	FH in Asian populations: ezetimibe recommended for patients not achieving LDL-C targets on statin monotherapy — clinically relevant for Singapore context
37762244	2023	Review	International Journal of Molecular Sciences	Postprandial hyperlipidemia pathophysiology and treatment: ezetimibe discussed as a therapeutic option targeting intestinal lipoprotein absorption to reduce atherogenic remnant particles

Singapore Market Information

Ezetimibe (DrugBank ID: DB00973) is currently not registered in Singapore. There are no active HSA product licenses as of the data cutoff (June 2026). This contrasts with its approval in all other major regulatory jurisdictions:

FDA (United States): Approved as Zetia® (monotherapy) and Vytorin® (ezetimibe/simvastatin fixed-dose combination)
EMA (Europe): Approved as Ezetrol® and Inegy® (with Merck/MSD)
PMDA (Japan): Approved as Zetia®, with 12-week and 52-week post-marketing surveillance datasets available

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Ezetimibe has Level 1 evidence — multiple completed Phase 3 RCTs, major international guideline endorsements, and regulatory approvals across the US, EU, and Japan — firmly supporting its efficacy and safety in hyperlipoproteinemia. The TxGNN model has correctly identified an established, globally validated clinical use. The primary barrier to deployment in Singapore is HSA registration, not clinical uncertainty.

To proceed, the following is needed:

Prepare and submit an HSA registration dossier, leveraging existing FDA/EMA approvals via the abridged evaluation pathway (referencing a well-established regulatory dossier)
Obtain and review the complete package insert (FDA, EMA, or PMDA approved labeling) for warnings, contraindications, and known drug interactions — particularly with statins, fibrates, and bile acid sequestrants
Retrieve formal mechanism of action and safety documentation from DrugBank to complete the pharmacological profile (currently flagged as a data gap)
Assess the Singapore patient population need, prescribing patterns, and potential MOH formulary inclusion pathway
Evaluate drug interaction profile for at-risk subpopulations, particularly patients on antiretroviral therapy (HIV-associated dyslipidemia), as this evidence gap was flagged in the DDI query log
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.